MENU
+Compare
AAPG
Stock ticker: NASDAQ
AS OF
Jun 20, 12:09 PM (EDT)
Price
$37.43
Change
+$1.55 (+4.32%)
Capitalization
3.12B

AAPG Ascentage Pharma Group Forecast, Technical & Fundamental Analysis

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases... Show more

AAPG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AAPG with price predictions
Jun 18, 2025

Momentum Indicator for AAPG turns positive, indicating new upward trend

AAPG saw its Momentum Indicator move above the 0 level on May 21, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 4 similar instances where the indicator turned positive. In of the 4 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for AAPG just turned positive on June 03, 2025. Looking at past instances where AAPG's MACD turned positive, the stock continued to rise in of 2 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

AAPG broke above its upper Bollinger Band on June 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AAPG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (84.746) is normal, around the industry mean (17.006). P/E Ratio (0.000) is within average values for comparable stocks, (59.274). AAPG's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.273). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (19.841) is also within normal values, averaging (256.503).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AAPG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
AAPG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GCV3.740.04
+1.08%
Gabelli Convertible and Income Securities Fund (The)
PMF7.870.01
+0.13%
PIMCO Municipal Income FUND
QQEW132.00-0.19
-0.14%
First Trust NASDAQ-100 Equal Wtd ETF
XSW181.14-0.65
-0.36%
SPDR® S&P Software & Services ETF
ABFL68.68-0.53
-0.76%
Abacus FCF Leaders ETF